The purpose of this Notice is to alert applicants of the early termination of PAR-24-062, “Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)”. The Notice of Funding Opportunity (NOFO), PAR-24-062, will be terminated, effective immediately. No further applications will be accepted for consideration under this NOFO.

A new PAR to support “Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)” will be issued to correct review criteria. Applications for the new PAR will be due beginning on March 17, 2025.

Applicants are encouraged to consider applying to the new PAR (expected to be published in February 2025): PAR-25-386, “Phased Research to Support Substance

Click this link to continue reading the article on the source website.

The purpose of this Notice is to alert applicants of the early termination of PAR-24-060, “Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)”. The Notice of Funding Opportunity (NOFO), PAR-24-060, will be terminated, effective immediately. No further applications will be accepted for consideration under this NOFO.

A new PAR to support “Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)” will be issued to correct review criteria. Applications for the new PAR will be due beginning on March 16, 2025.

Applicants are encouraged to consider applying to the new NOFO (expected to be published in February 2025): PAR-25-388 “Pilot and Feasibility Studies in

Click this link to continue reading the article on the source website.

The Notice informs potential applicants that the U.S. Environmental Protection Agency (EPA) is participating, effective immediately, in the notice of funding opportunity (NOFO), RFA-RM-24-010, Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional). Changes to the NOFO are shown below.

The following section of RFA-RM-24-010 was modified:

Part I. Overview Information

Participating Organization(s)

Currently Reads:

National Institutes of Health (NIH)

Modified to Read (changes shown in bold italics):

National Institutes of Health (NIH)

U.S. Environmental Protection Agency (EPA)

All other aspects of the NOFO remain the same.

Click this link to continue reading the article on the source website.

Alzheimer’s disease (AD) is defined, in part, by the appearance of extracellular amyloid deposits. Supported by genetic studies, the amyloid cascade is a leading hypothesis for the cause and pathogenesis of AD. Despite the intensive efforts that have been made in understanding amyloid and other pathological processes in AD, current approved interventions for AD have shown only modest effects in modifying clinical symptoms; none have been efficacious for slowing disease progression as demonstrated through clinical outcome measures.

Recent developments in the field of genetics have significantly advanced understanding of the etiology of AD. More than two dozen genes are now known to be associated with late-onset AD (LOAD). Using a combination of genome-wide association studies (GWAS),

Click this link to continue reading the article on the source website.